Abstract 456P
Background
As mentioned by ESMO guidelines on the management of constipation in advanced cancer, combined opiate/naloxone medications have been shown to reduce the risk of OIC through a range of studies. Oxycodone/naloxone prolonged-release tablets (OXN PR) provide similar efficacy, but an improved bowel function compared with oxycodone prolonged-release tablets (OXY PR). This is the first Chinese study about OXN PR in cancer pain population.
Methods
This multi-center, randomized, double-blind controlled trial compared OXN PR to OXY PR for 4 weeks in adult cancer patients with moderate-to-severe pain and OIC. Primary efficacy endpoints: Bowel Function Index (BFI) and Brief Pain Inventory-Short Form (BPI-SF). Key secondary endpoints: use of laxative (bisacodyl tablets) and rescue analgesia (morphine sulfate), quality of life (EQ-5D) and safety.
Results
232 patients were randomized (117 in the OXN PR group; 115 in the OXY PR group). BPI-SF average pain was comparable after 4 weeks between OXN PR and OXY PR groups. The difference of average BFI at 4 weeks was not statistically significant between the 2 treatment groups (FAP, p=0.482). Compared to baseline, a BFI reduction was seen after 1 week in OXN PR group (13.5 points vs. 8.8 points in OXY PR group; p=0.039). Results of an exploratory post-hoc analysis confirmed these findings, with the BFI difference favoring OXN PR. Laxative use was similar between the 2 groups, but a higher percentage of patients required laxatives in OXY PR group compared to OXN PR group at all visits. Average daily dose and percentage of patients taking rescue analgesia were similar at 4 weeks. EQ-5D assessment showed a minor improvement in the OXN PR group and a decline in OXY PR group (non-significant). Fewer adverse events were reported in the OXN PR group (17.5% vs. 27.0% in the OXY PR group); No treatment-related SAEs were reported with OXN PR group.
Conclusions
In managing moderate-to-severe cancer pain among Chinese patients, OXN PR has demonstrated comparable efficacy to OXY PR. Improvements of bowel function were numerically observed and statistically confirmed by a post-hoc analysis (p=0.039). This study adds to the wealth of evidence around the positive benefit/risk profile of OXN PR in an Asian population.
Clinical trial identification
NCT00513656.
Editorial acknowledgement
Editorial assistance was provided by MedAcc Technology Co., Ltd.
Legal entity responsible for the study
Mundipharma (China) Pharmaceutical Co.LTD.
Funding
Mundipharma (China) Pharmaceutical Co.LTD.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract